Repligen
RGEN
#1859
Rank
A$16.07 B
Marketcap
A$251.51
Share price
2.97%
Change (1 day)
12.20%
Change (1 year)
Categories

Repligen (RGEN) - Total liabilities

Total liabilities on the balance sheet as of June 2026 : A$1.21 Billion

According to Repligen 's latest financial reports the company's total liabilities are A$1.21 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Repligen - Total liabilities on balance sheet (from 2001 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31A$1.25 B38.81%
2022-12-31A$0.90 B7.53%
2021-12-31A$0.83 B72.62%
2020-12-31A$0.48 B-0.01%
2019-12-31A$0.48 B115.31%
2018-12-31A$0.22 B15.98%
2017-12-31A$0.19 B16.78%
2016-12-31A$0.16 B416.95%
2015-12-31A$32.24 M59.34%
2014-12-31A$20.23 M22.3%
2013-12-31A$16.54 M33.44%
2012-12-31A$12.39 M
2011-03-31A$5.03 M-12.46%
2010-03-31A$5.75 M-13.12%
2009-03-31A$6.62 M28.94%
2008-03-31A$5.13 M17.36%
2007-03-31A$4.37 M-2.4%
2006-03-31A$4.48 M4.49%
2005-03-31A$4.29 M31.98%
2004-03-31A$3.25 M-12.53%
2003-03-31A$3.71 M-25.6%
2002-03-31A$4.99 M92.2%
2001-03-31A$2.6 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Pfizer
PFE
A$167.64 B 13,696.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
A$87.51 B 7,102.31%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
A$158.66 B 12,957.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
A$94.76 B 7,699.10%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
A$0.11 B-90.58%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
A$1.66 B 36.76%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
A$2.41 B 98.71%๐Ÿ‡บ๐Ÿ‡ธ USA
Bio-Techne
TECH
A$0.69 B-42.91%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
A$7.83 B 544.49%๐Ÿ‡บ๐Ÿ‡ธ USA
Charles River Laboratories
CRL
A$6.73 B 454.03%๐Ÿ‡บ๐Ÿ‡ธ USA